ISPAD 2021 welcomes the submission of abstracts that make an original contribution to the field. All abstracts submitted will go through a blind, peer-review process carried out by an international review panel. Each abstract will be reviewed by at least two reviewers and the final selection of abstracts will be completed by members of the Abstract Review Committee.
All accepted abstracts will appear online in their full form, which will be issued as a special supplement of ISPAD’s Journal Pediatric Diabetes.
- The deadline for abstract submission is midnight Central European Time (CET) on 23 July 2021 at 23:59 CET. Abstracts will not be accepted after this date.
- All abstracts must be written in English and in “Sentence case.”
- All abstracts must be submitted online via the registration form.
- Abstracts sent by fax, post or email will not be considered. It is the author’s responsibility to submit a correct abstract. Any errors in spelling, grammar or scientific fact will be reproduced as submitted by the author.
- Please note that it is still possible to edit an abstract, even after clicked “submit”, until the end of the deadline
- The text should not exceed 2,000 characters including spaces. One table or figure can be inserted, but kindly note that 50 characters per table/figure will be removed from your total abstract count. The text of the abstract should briefly state:
- Objectives: Indicate the purpose of the study or the hypothesis that was tested.
- Methods: Include the setting for the study, the subjects, the diagnosis or intervention, and the type of statistical analysis. If references are needed, they should be provided in the text.
- Results: Present as clearly as possible the outcome of the study and after significance if appropriate
- Conclusions: Briefly discuss the data and emphasize the significance of the results. All abstracts should disclose primary findings and avoid, whenever possible, promissory statements such as “experiments are in progress “or “results will be discussed“.
Rule of Two
Each presenting author may present a maximum of two abstracts at the Conference. There is no limit to the number of abstracts which may be submitted by one author.
The abstract categories are the general heading under which abstracts will be submitted and reviewed.
- Diabetes and COVID-19
- Diabetes and Technology
- Pumps and CGM
- Automated Insulin Delivery, Closed loop
- Telemedicine, Digital Health, Decision Support and Artificial Intelligence Applications
- Diabetes Pathogenesis, Epidemiology and Etiology
- Diabetes Care
- Virtual Diabetes Care
- Diabetes at School
- Economics/Access to Care
- Ethics of Care
- General Diabetes Care
- Diabetes Therapy and Prevention
- Adjunctive Therapies
- New insulins
- Other Pharmacologic Agents
- Novel Advances and Interventions
- Diabetes Education
- Diabetes Complications
- Acute Complications
- Chronic Complications
- Childhood Obesity and Type 2 Diabetes
- Diabetes in Developing Countries and Migrant Populations
- Diabetes-Associated Diseases
- Genetics, Imunology and the Environment
- Monogenic and other forms of Diabetes
- Psychosocial Issues
Notification of Acceptance or Rejection
Notification of acceptance or rejection will be sent to the corresponding author by the end of September 2021. Please note that only the corresponding author will receive this email concerning the abstract and is responsible for informing all co-authors of the status of the abstract. Authors whose abstracts have been accepted will receive instructions for the presentation of their abstract.
It is not allowed to submit an abstract that has been published and/or is likely to be published before the ISPAD Abstract submission deadline (23 July 2021 23:59 hrs. CET). The Scientific Committee has the right to withdraw an abstract if this data has already been published. However, ISPAD accepts the submission of abstracts that have been presented in recent months at local, national or regional diabetes meetings (e.g. ADA, DDG, EASD).
Late breaking abstract submission
NOTE: due to the extension of the submission and reviewing abstract process, there will be exceptionally NO late breakers abstracts submission this year.